Huntington's Disease Supportive Care Protocol
Primary Stack
Core supplements with strongest evidenceSupports mitochondrial function which is impaired in Huntington's; has neuroprotective potential
May support brain energy metabolism; studied for neuroprotection in Huntington's
Supporting Stack
Additional supplements for enhanced resultsMay have neuroprotective effects through anti-inflammatory mechanisms
Supporting Studies (1)
Antioxidant that may help protect against oxidative stress in neurodegeneration
Supporting Studies (1)
SIRT1 activator with potential neuroprotective effects; studied in HD models
Supporting Studies (1)
Deficiency common; vitamin D has neuroprotective and anti-inflammatory effects
Supporting Studies (1)
Anti-inflammatory and antioxidant; shown protective in HD animal models
Supporting Studies (1)
Support energy metabolism and may help with fatigue and cognitive function
Supporting Studies (1)
Glutathione precursor that may reduce oxidative stress in neurodegeneration
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Huntington's disease (HD) is an inherited neurodegenerative disorder caused by a mutation in the huntingtin gene (expanded CAG repeats). It typically begins in middle age (30s-40s) and causes progressive movement problems (chorea - involuntary movements), cognitive decline, and psychiatric symptoms. The disease gradually affects the basal ganglia and cortex of the brain. Currently, there is no cure and no treatment that slows the disease progression, though symptoms can be managed.
CRITICAL: Huntington's disease requires specialized neurology care, preferably at an HD center. Standard treatments manage symptoms (tetrabenazine/deutetrabenazine for chorea, antidepressants, antipsychotics as needed). Gene-silencing therapies are in development. Genetic counseling is essential for family members. These supplements are experimental and supportive only - they have NOT been proven to slow disease progression.
* Coenzyme Q10 has been the most studied supplement in HD. The disease involves mitochondrial dysfunction and energy deficits, and CoQ10 supports mitochondrial function. While early studies were promising, larger trials have shown mixed results. It remains one of the most commonly used supplements among HD patients.
* Creatine supports brain energy metabolism. The CREST-E trial studied high-dose creatine but did not show significant benefit in slowing disease progression. However, it may still provide energy support.
* Omega-3 Fatty Acids have anti-inflammatory and potentially neuroprotective effects. A pilot study in HD patients showed some benefit, but larger studies are needed.
* Vitamin E is an antioxidant that may help with oxidative stress, which contributes to neurodegeneration in HD.
* Resveratrol activates SIRT1 and has shown protective effects in HD animal models, though human data is limited.
* Vitamin D deficiency is common in HD patients, partly due to reduced sun exposure. Maintaining adequate levels supports overall health.
* Curcumin has shown promise in HD animal models through its anti-inflammatory effects.
* B Vitamins support energy metabolism and overall brain health.
* NAC is a glutathione precursor that may help with oxidative stress.
Expected timeline: No supplements have been proven to slow HD progression. They may provide supportive benefit for energy, mood, and general health. Clinical trials of new disease-modifying therapies are ongoing.
Clinical Perspective
Huntington's disease: autosomal dominant neurodegenerative disorder from expanded CAG repeats (>36) in huntingtin gene (HTT). Repeat length correlates with age of onset (longer = earlier). Prevalence: 5-10 per 100,000 Caucasians. Neuropathology: striatal atrophy (caudate, putamen), cortical atrophy. Pathogenesis: mutant huntingtin aggregation, transcriptional dysregulation, mitochondrial dysfunction, excitotoxicity, oxidative stress.
CRITICAL: HD requires specialized multidisciplinary care at HD centers. Genetic testing with pre-test and post-test counseling. No disease-modifying therapy FDA-approved (gene-silencing therapies in trials). Symptomatic management: tetrabenazine/deutetrabenazine (VMAT2 inhibitors) for chorea; SSRIs/SNRIs for depression; antipsychotics for psychosis/agitation. Physical, occupational, speech therapy. Nutritional support (high caloric needs). Supplements are EXPERIMENTAL - none proven to slow progression.
* CoQ10 (B-grade): Mitochondrial electron carrier; antioxidant. Systematic review: some positive signals but definitive benefit not proven (PMID: 20833324). Randomized trial: trend toward slowing decline (PMID: 11456302). 600-1200mg daily. 2CARE trial (2400mg) did not show benefit. Ubiquinol may be better absorbed.
* Creatine (C-grade): Phosphocreatine shuttle supports brain energy. CREST-E trial: 40g daily did not slow functional decline (PMID: 25156012). Safety study: well-tolerated (PMID: 16835258). May still provide energy support. 10-40g daily.
* Omega-3 Fatty Acids (C-grade): DHA is major brain lipid; anti-inflammatory. Pilot study: ethyl-EPA showed some improvement in chorea (PMID: 18728104). 2-4g EPA+DHA daily.
* Vitamin E (C-grade): Antioxidant. Clinical trial: no significant benefit in early HD (PMID: 8592323). May still help with oxidative stress. 400-2000 IU daily.
* Resveratrol (C-grade): SIRT1 activator; neuroprotective in HD models. Review: promising preclinical data (PMID: 20818766). Limited human HD data. 200-1000mg daily.
* Vitamin D (C-grade): Neuroprotective; deficiency common in HD. Review: role in neurodegeneration (PMID: 25634657). Check 25(OH)D; target 40-60 ng/mL. 2000-4000 IU daily.
* Curcumin (C-grade): Anti-inflammatory; reduces huntingtin aggregation in models. Review: preclinical promise (PMID: 21695651). 500-1500mg bioavailable form daily.
* B Vitamins (C-grade): Energy metabolism support. Review: role in neurodegeneration (PMID: 17658628). B-complex with adequate B12, folate.
* NAC (C-grade): Glutathione precursor; antioxidant. Review: potential in neurodegeneration (PMID: 25072742). 600-1800mg daily.
Biomarker targets: UHDRS (Unified Huntington Disease Rating Scale - motor, cognitive, behavioral, functional), volumetric MRI (striatal volume), NfL (neurofilament light - emerging biomarker), weight maintenance.
Protocol notes: Refer to HD Society of America centers. Genetic counseling for at-risk family members (50% risk for each child). Preimplantation genetic testing available. Predictive testing with strict protocols. Manage chorea: deutetrabenazine (Austedo) preferred due to less depression risk than tetrabenazine. Treat depression aggressively - high suicide risk. Antipsychotics for irritability/psychosis. Avoid dopamine antagonists that worsen motor function if possible. Swallowing evaluation - aspiration risk. High calorie diet (hypermetabolism). Speech therapy. PT/OT for function. Support groups. Respite care. Advance directives early. HDSA clinical trials - encourage participation. Gene-silencing therapies (antisense oligonucleotides, siRNA) in trials may be disease-modifying. Juvenile HD (<20 years) has different presentation (rigidity, seizures, rapid progression).